Furthermore, by studying prostate tissue specimens from prostate cancer patients a direct correlation between presence of mtDNA large deletions and loss of BRCA2 protein in vivo was found, suggesting that mtDNA status might serve as a marker to predict therapeutic efficacy to PARP inhibitors. Here, BRCA2 is linked to prostate cancer.